Coagulopathies and thrombosis: Usual and unusual causes and associations, part VI

Seminars in Thrombosis and Hemostasis

Volumn 38, Issue 2, 2012, Pages 125-128

  Lippi, Giuseppe ^a   Favaloro, Emmanuel J ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 7A; FIBRIN; FIBRINOGEN; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; RIVAROXABAN; TISSUE FACTOR PATHWAY INHIBITOR;

ACUTE CORONARY SYNDROME; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; EDITORIAL; HEPARIN INDUCED THROMBOCYTOPENIA; HYPERCOAGULABILITY; IMMUNOASSAY; LUNG EMBOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PRIORITY JOURNAL; RED WINE; RISK REDUCTION; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; VON WILLEBRAND DISEASE;

ACUTE CORONARY SYNDROME; ALTITUDE; BLOOD COAGULATION DISORDERS; COFFEE; FACTOR XA; HEPARIN; HUMANS; LIPOPROTEINS; LYMPHATIC DISEASES; MORPHOLINES; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; THIOPHENES; THROMBOCYTOPENIA; THROMBOSIS; TROPONIN; VENOUS THROMBOSIS; VON WILLEBRAND DISEASES;

EID: 84858127183     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0032-1301409     Document Type: Editorial

References (39)

1. Franchini M, Lippi G, Favaloro EJ. Coagulopathies and thrombosis: usual and unusual causes and associations, part I. Semin Thromb Hemost: 2009; 35 3 257 259
2. Lippi G, Franchini M, Favaloro EJ. Coagulopathies and thrombosis: usual and unusual causes and associations, Part II. Semin Thromb Hemost: 2009; 35 7 591 595
3. Favaloro EJ, Lippi G, Franchini M. Coagulopathies and thrombosis: usual and unusual causes and associations, part III. Semin Thromb Hemost: 2010; 36 1 1 5
4. Lippi G, Favaloro EJ, Franchini M. Coagulopathies and thrombosis: usual and unusual causes and associations, Part IV. Semin Thromb Hemost: 2011; 37 3 175 180
5. Favaloro EJ, Franchini M, Lippi G. Coagulopathies and thrombosis: usual and unusual causes and associations. Part v. Semin Thromb Hemost: 2011; 37 8 859 862
6. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol: 2011; 8 9 502 512
7. Montagnana M, Favaloro EJ, Franchini M, Guidi GC, Lippi G. The role of ethnicity, age and gender in venous thromboembolism. J Thromb Thrombolysis: 2010; 29 4 489 496
8. Adams M. Tissue factor pathway inhibitor: new insights into an old inhibitor. Semin Thromb Hemost: 2012; 38 2 129 134
9. Kasthuri RS, Glover SL, Boles J, Mackman N. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost: 2010; 36 7 764 771
10. Tan CW, Ward CM, Morel-Kopp M-C. Evaluating heparin-induced thrombocytopenia: the old and the new. Semin Thromb Hemost: 2012; 38 2 135 143
11. Bikdeli B, Sharif-Kashani B. Prophylaxis for venous thromboembolism: a great divide between expert guidelines and clinical practice? Semin Thromb Hemost: 2012; 38 2 144 155
12. Kannan M, Saxena R, Adiguzel C, Fareed J. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients. Semin Thromb Hemost: 2009; 35 3 337 343
13. Linkins LA, Warkentin TE. Heparin-induced thrombocytopenia: real-world issues. Semin Thromb Hemost: 2011; 37 6 653 663
14. Lassila R, Antovic JP, Armstrong E., et al. Practical viewpoints on the diagnosis and management of heparin-induced thrombocytopenia. Semin Thromb Hemost: 2011; 37 3 328 336
15. Tufano A, Coppola A, Cerbone AM, Ruosi C, Franchini M. Preventing postsurgical venous thromboembolism: pharmacological approaches. Semin Thromb Hemost: 2011; 37 3 252 266
16. Lippi G, Favaloro EJ, Cervellin G. Prevention of venous thromboembolism: focus on mechanical prophylaxis. Semin Thromb Hemost: 2011; 37 3 237 251
17. Lippi G, Franchini M, Favaloro EJ. Unsuspected triggers of venous thromboembolismtrivial or not so trivial? Semin Thromb Hemost: 2009; 35 7 597 604
18. Lippi G, Franchini M, Favaloro EJ. Holiday thrombosis. Semin Thromb Hemost: 2011; 37 8 869 874
19. Gallus AS. Travel, venous thromboembolism, and thrombophilia. Semin Thromb Hemost: 2005; 31 1 90 96 (Pubitemid 40262142)
20. Gupta N, Ashraf MZ. Exposure to high altitude: a risk factor for venous thromboembolism? Semin Thromb Hemost: 2012; 38 2 156 163
21. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost: 2008; 34 8 747 761
22. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradoxo" Semin Thromb Hemost: 2010; 36 1 59 70
23. Phang M, Lazarus S, Wood LG, Garg M. Diet and thrombosis risk: nutrients for prevention of thrombotic disease. Semin Thromb Hemost: 2011; 37 3 199 208
24. Montagnana M, Favaloro EJ, Lippi G. Coffee intake and cardiovascular disease: virtue does not take center stage. Semin Thromb Hemost: 2012; 38 2 164 177
25. Lippi G, Franchini M, Targher G. Rivaroxaban for thromboprophylaxis. N Engl J Med: 2008; 359 20 2174, author reply 2175-2176
26. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med: 2011; 49 5 761 772
27. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against? Clin Chem Lab Med: 2011; 49 5 755 757
28. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology: 2011; 43 7 682 692
29. Lippi G, Franchini M, Favaloro EJ. Pharmacogenetics of vitamin K antagonists: useful or hype? Clin Chem Lab Med: 2009; 47 5 503 515
30. Harenberg J, Erdle S, Marx S, Krämer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost: 2012; 38 2 178 184
31. Franchini M, Coppola A. Atherothrombosis in von Willebrand disease: an analysis of the literature and implications for clinical management. Semin Thromb Hemost: 2012; 38 2 185 199
32. Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res: 2011; 127 Suppl 2 S17 S21
33. Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost: 2011; 37 5 440 455
34. Linden MD, Tran H, Woods R, Tonkin A. High platelet reactivity and antiplatelet therapy resistance. Semin Thromb Hemost: 2012; 38 2 200 212
35. Lippi G, Favaloro EJ, Cervellin G. Hemostatic properties of the lymph: relationships with occlusion and thrombosis. Semin Thromb Hemost: 2012; 38 2 213 221
36. Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. Semin Thromb Hemost: 2012; 38 2 222 229
37. Cardinale D, Salvatici M, Sandri MT. Review: role of biomarkers in cardioncology. Clin Chem Lab Med: 2011;; September 6 [Epub ahead of print], DOI:10.1515/CCLM.2011.692
38. Christ M, Bertsch T, Popp S, Bahrmann P, Heppner HJ, Müller C. High-sensitivity troponin assays in the evaluation of patients with acute chest pain in the emergency department. Clin Chem Lab Med: 2011;; September 6 [Epub ahead of print], DOI: 10.1515/CCLM.2011.695
39. Grifoni E, Marcucci R, Ciuti G., et al. The thrombophilic pattern of different clinical manifestations of venous thromboembolism: a survey of 443 cases of venous thromboembolism. Semin Thromb Hemost: 2012; 38 2 230 234